SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 27, 2022--
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year.
The annual award is based solely on employee feedback gathered through an anonymous, third-party survey administered by Energage, LLC. The survey measures 15 culture drivers that are critical to organizational success, including alignment, execution, and connection. On average, fewer than three percent of eligible organizations earn a Top Workplaces designation.
Veracyte employees participating in the survey ranked the company most highly for fostering strong interdepartmental cooperation and doing things efficiently and well. When asked to describe Veracyte’s culture in three words, employees most often referred to the company as “flexible,” “friendly,” and “collaborative.”
“We are honored that Veracyte has been recognized as a Bay Area Top Workplace for the ninth consecutive year,” said Marc Stapley, Veracyte’s chief executive officer. “I truly believe our employees are our greatest asset and are key to helping us achieve our vision of improving outcomes for patients all over the world. It’s gratifying to see that our focus on our people and culture is reflected in our employees’ daily experiences.”
The San Francisco Chronicle published the complete list of 2022 Top Workplaces winners on Sunday, June 26. The complete list of awardees can be found here.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the 10 most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220627005197/en/
Investors:
Shayla Gorman
Director, Investor Relations
investors@veracyte.com
619-393-1545
Media:
Tracy Morris
Vice President, Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413
Source: Veracyte, Inc.